Patents by Inventor Xiaojun Lu

Xiaojun Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11145344
    Abstract: A method includes performing a first read operation on a memory cell of a programmed first one-time programmable (OTP) anti-fuse to determine a state of the memory cell based on a first parameter level, performing a second read operation on the memory cell of the programmed first OTP anti-fuse to determine the state of the memory cell based on a second parameter level, identifying the memory cell of the first OTP anti-fuse as an uncertain bit when the state determined during the first read operation and the state determined during the second read operation are different, and programing one or more memory cells of a second OTP anti-fuse based on a bit position of the identified uncertain bit of the first OTP anti-fuse.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 12, 2021
    Assignee: Synopsys, Inc.
    Inventor: Xiaojun Lu
  • Patent number: 10867674
    Abstract: A memory storage device is disclosed herein which having volatile memory cells and non-volatile memory cells. The memory storage device can be implemented within a portable electronic device. These portable electronic devices often load data from non-volatile memory cells into volatile memory cells, for example, upon powering up. Conventionally, portable electronic devices often include separate non-volatile memory storage devices and volatile memory storage devices which requires a significant amount of time to transfer data stored in non-volatile memory storage devices to the volatile memory storage devices. However, the memory storage device integrates the volatile memory cells and the non-volatile memory cells into a single integrated memory device.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 15, 2020
    Assignee: Synopsys, Inc.
    Inventor: Xiaojun Lu
  • Patent number: 10751683
    Abstract: A reactor, which includes a reactor body and two reactor ends sealing the ends of the reactor body, a plurality of reactor tubes extending inside the reactor body at least partially between the reactor ends, and at least one heat pipe disposed inside at least one of the reactor tubes.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 25, 2020
    Assignee: UNISA
    Inventors: David Glasser, Xiaojun Lu, Diane Hildebrandt
  • Publication number: 20200079877
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 12, 2020
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 10556968
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20190292274
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: April 4, 2019
    Publication date: September 26, 2019
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui HUANG, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20180194858
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 9938356
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: April 10, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20170312723
    Abstract: A reactor, which includes a reactor body and two reactor ends sealing the ends of the reactor body, a plurality of reactor tubes extending inside the reactor body at least partially between the reactor ends, and at least one heat pipe disposed inside at least one of the reactor tubes.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 2, 2017
    Inventors: David GLASSER, Xiaojun LU, Diane HILDEBRANDT
  • Patent number: 9411870
    Abstract: System and method for location aware fine-grained multi-channel synchronization of mobile repositories along with aggregate analytic computation is disclosed. The System is able to improve upon existing systems by allowing for custom policies on synchronization to be stored and applied when data synchronization happens, these policies are persisted in the Sync Data Repository and applied during sync. The System is able to improve upon existing systems by allowing for persistent marking of states of the sync repository as Sync Points. This way data can be pulled from a sync point. The System is able to improve upon existing systems by having a computation framework that is able to push down aggregate analytics to user, these analytics are computed by analyzing data in the Sync Channel along various dimensions such as temporal, geo.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: August 9, 2016
    Assignee: iData Crunch
    Inventors: Ramkartik Mulukutla, Xiaojun Lu
  • Publication number: 20160194407
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20140337289
    Abstract: System and method for location aware fine-grained multi-channel synchronization of mobile repositories along with aggregate analytic computation is disclosed. The System is able to improve upon existing systems by allowing for custom policies on synchronization to be stored and applied when data synchronization happens, these policies are persisted in the Sync Data Repository and applied during sync. The System is able to improve upon existing systems by allowing for persistent marking of states of the sync repository as Sync Points. This way data can be pulled from a sync point. The System is able to improve upon existing systems by having a computation framework that is able to push down aggregate analytics to user, these analytics are computed by analyzing data in the Sync Channel along various dimensions such as temporal, geo.
    Type: Application
    Filed: April 25, 2014
    Publication date: November 13, 2014
    Inventors: Ramkartik Mulukutla, Xiaojun Lu